GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (LTS:0QDU) » Definitions » Short Interest

Abliva AB (LTS:0QDU) Short Interest


View and export this data going back to 2013. Start your Free Trial

What is Abliva AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Abliva AB's Short Interest

For the Biotechnology subindustry, Abliva AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abliva AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Abliva AB's Short Interest falls into.


Abliva AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (LTS:0QDU) » Definitions » Short Interest
Comparable Companies
OSTO:ATORX XSAT:HAMLET B OSTO:BIOWKS OSTO:MAGLE OSTO:ACOU OSTO:KAN OSTO:ACTI OSTO:CLBIO OSTO:STABL OSTO:GUARD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ABLI:Sweden NTP:Germany
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Website
https://www.abliva.com
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.

Abliva AB Headlines

No Headlines